Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.
Institute of Human Genetics, University of Ulm, Ulm, Germany.
Gastroenterology. 2018 Jan;154(1):181-194.e20. doi: 10.1053/j.gastro.2017.09.005. Epub 2017 Sep 12.
BACKGROUND & AIMS: Although there is a genetic predisposition to colorectal cancer (CRC), few of the genes that affect risk have been identified. We performed whole-exome sequence analysis of individuals in a high-risk family without mutations in genes previously associated with CRC risk to identify variants associated with inherited CRC.
We collected blood samples from 3 relatives with CRC in Spain (65, 62, and 40 years old at diagnosis) and performed whole-exome sequence analyses. Rare missense, truncating or splice-site variants shared by the 3 relatives were selected. We used targeted pooled DNA amplification followed by next generation sequencing to screen for mutations in candidate genes in 547 additional hereditary and/or early-onset CRC cases (502 additional families). We carried out protein-dependent yeast growth assays and transfection studies in the HT29 human CRC cell line to test the effects of the identified variants.
A total of 42 unique or rare (population minor allele frequency below 1%) nonsynonymous genetic variants in 38 genes were shared by all 3 relatives. We selected the BRF1 gene, which encodes an RNA polymerase III transcription initiation factor subunit for further analysis, based on the predicted effect of the identified variant and previous association of BRF1 with cancer. Previously unreported or rare germline variants in BRF1 were identified in 11 of 503 CRC families, a significantly greater proportion than in the control population (34 of 4300). Seven of the identified variants (1 detected in 2 families) affected BRF1 mRNA splicing, protein stability, or expression and/or function.
In an analysis of families with a history of CRC, we associated germline mutations in BRF1 with predisposition to CRC. We associated deleterious BRF1 variants with 1.4% of familial CRC cases, in individuals without mutations in high-penetrance genes previously associated with CRC. Our findings add additional evidence to the link between defects in genes that regulate ribosome synthesis and risk of CRC.
虽然结直肠癌(CRC)存在遗传易感性,但影响风险的基因很少被确定。我们对一个无先前与 CRC 风险相关基因突变的高危家族中的个体进行了全外显子组序列分析,以鉴定与遗传性 CRC 相关的变体。
我们收集了来自西班牙的 3 名 CRC 患者的血液样本(诊断时年龄分别为 65 岁、62 岁和 40 岁),并进行了全外显子组序列分析。选择 3 名亲属共享的罕见错义、截断或剪接位点变异。我们使用靶向 DNA 扩增池随后进行下一代测序,以筛选 547 例遗传性和/或早发性 CRC 病例(502 个额外的家族)中的候选基因中的突变。我们在 HT29 人 CRC 细胞系中进行了依赖于蛋白质的酵母生长测定和转染研究,以测试鉴定变体的影响。
在 3 名亲属中共享了 38 个基因中的 42 个独特或罕见(人群中次要等位基因频率低于 1%)的非同义遗传变异。我们根据鉴定的变异的预测影响以及 BRF1 先前与癌症的关联,选择了 BRF1 基因(编码 RNA 聚合酶 III 转录起始因子亚基)进行进一步分析。在 503 个 CRC 家族中的 11 个家族中发现了 BRF1 中的先前未报告或罕见的种系变体,这一比例明显高于对照组(4300 个中的 34 个)。鉴定的 7 个变体(在 2 个家族中检测到 1 个)影响 BRF1 mRNA 剪接、蛋白质稳定性或表达和/或功能。
在对有 CRC 病史的家族进行的分析中,我们将 BRF1 中的种系突变与 CRC 的易感性联系起来。我们将有害的 BRF1 变体与先前与 CRC 相关的高外显率基因无突变的家族性 CRC 病例的 1.4%联系起来。我们的发现为核糖体合成相关基因缺陷与 CRC 风险之间的联系提供了更多证据。